Evolent Q2 revenue $652.5M (+47% YoY); net loss narrows; new oncology partnership to add $300M annual revenue

Evolent Health, Inc.

Revenue $652.5M vs $444.3M YoY; net loss attributable to common $28.4M vs $51.1M.
Adjusted EBITDA $28.1M (4.3% margin) vs $37.5M (8.5% margin) YoY; Medical Expense Ratio 95.3% vs 80.0%.
Guides 2027 revenue growth >25% vs 2026; midpoint of 2027 Adjusted EBITDA at or above $150M.
New Oncology Performance Suite partnership covering ~1.5M lives, expected launch Dec 2026, ~$300M annualized revenue.
Existing STSS client expands; annualized revenue <$5M; company evaluating debt reduction initiatives.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.